Live Breaking News & Updates on Karan Verma

Stay updated with breaking news from Karan verma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China

By Andrew Silver SHANGHAI (Reuters) - Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatmen. ....

Maggie Fick , Andrew Silver , Zuo Ya Jun , Miyoung Kim , Clarivate Verma , Karan Verma , Eli Lilly , Muralikumar Anantharaman , Jacob Gronholt Pedersen , Maziar Mike Doustdar , Novo Nordisk , Sihuan Pharmaceutical Holdings Group , Goldman Sachs , Danish Krone , Hangzhou Jiuyuan Gene Engineering , United Laboratories , Huadong Medicine , Sihuan Pharmaceutical Holdings , Shanghai Benemae Pharmaceutical ,

Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China

SHANGHAI (Reuters) -Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world's highest number of people who are overweight or obese. Ozempic won approval from China in 2021 and Novo Nordisk saw sales of the drug in the greater China region double to 4.8 billion Danish Krone ($698 million) last year. ....

Zuo Ya Jun , Jacob Gronholt Pedersen , Clarivate Verma , Muralikumar Anantharaman , Maggie Fick , Andrew Silver , Karan Verma , Maziar Mike Doustdar , Eli Lilly , Miyoung Kim , Sihuan Pharmaceutical Holdings Group , Goldman Sachs , Novo Nordisk , Danish Krone , Hangzhou Jiuyuan Gene Engineering , United Laboratories , Huadong Medicine , Sihuan Pharmaceutical Holdings , Shanghai Benemae Pharmaceutical ,

Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China

SHANGHAI (Reuters) -Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world's highest number of people who are overweight or obese. Ozempic won approval from China in 2021 and Novo Nordisk saw sales of the drug in the greater China region double to 4.8 billion Danish Krone ($698 million) last year. ....

Maggie Fick , Clarivate Verma , Muralikumar Anantharaman , Jacob Gronholt Pedersen , Zuo Ya Jun , Miyoung Kim , Eli Lilly , Karan Verma , Andrew Silver , Maziar Mike Doustdar , Novo Nordisk , Goldman Sachs , Sihuan Pharmaceutical Holdings Group , Danish Krone , Hangzhou Jiuyuan Gene Engineering , United Laboratories , Huadong Medicine , Sihuan Pharmaceutical Holdings , Shanghai Benemae Pharmaceutical ,